Theravance Biopharma (NASDAQ:TBPH) Announces Earnings Results

Theravance Biopharma (NASDAQ:TBPH) announced its earnings results on Monday. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.18), FiscalAI reports. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%.The company had revenue of $20.73 million for the quarter, compared to analysts’ expectations of $22.49 million.

Theravance Biopharma Stock Down 0.1%

NASDAQ:TBPH opened at $16.91 on Tuesday. Theravance Biopharma has a 52 week low of $11.30 and a 52 week high of $21.03. The company has a fifty day simple moving average of $16.79 and a two-hundred day simple moving average of $16.89. The company has a market cap of $871.71 million, a price-to-earnings ratio of 7.69 and a beta of 0.19.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Zacks Research cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 8th. BTIG Research lowered Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 29th. JonesTrading lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, June 29th. Wall Street Zen lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, HC Wainwright downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $15.00 to $17.00 in a report on Tuesday, July 7th. Eight investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $19.40.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, major shareholder Eli Samaha sold 37,799 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $17.00, for a total transaction of $642,583.00. Following the completion of the transaction, the insider owned 9,174,453 shares in the company, valued at $155,965,701. The trade was a 0.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Rhonda Farnum sold 13,314 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $16.39, for a total transaction of $218,216.46. Following the completion of the sale, the senior vice president directly owned 232,457 shares in the company, valued at approximately $3,809,970.23. This represents a 5.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 350,011 shares of company stock worth $6,008,309. Insiders own 7.65% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

Institutional investors and hedge funds have recently modified their holdings of the company. AQR Capital Management LLC acquired a new stake in Theravance Biopharma in the first quarter valued at $101,000. Jane Street Group LLC boosted its position in shares of Theravance Biopharma by 169.2% during the 1st quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock worth $1,258,000 after acquiring an additional 88,540 shares in the last quarter. Creative Planning purchased a new position in shares of Theravance Biopharma in the 2nd quarter valued at about $139,000. American Century Companies Inc. raised its position in shares of Theravance Biopharma by 6.8% during the 2nd quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock worth $1,009,000 after acquiring an additional 5,794 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Theravance Biopharma by 12.4% during the 2nd quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company’s stock worth $279,000 after acquiring an additional 2,789 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.